Therefore, the Ki67 immunohistochemistry assay might offer a cost-effective alternative.13–15 The 2015 St Gallen consensus panel stated that the majority of new breast cancer cases and breast cancer deaths now occur in less developed regions of the world,13 accentuating the need for low cost, widely accessible biomarkers. Here, MKI67 is linked to breast carcinoma.